Cytapheresis in Patients with Severe Ulcerative Colitis after Failure of Intravenous Corticosteroid: A Long-Term Retrospective Cohort Study
2
조회
0
다운로드
1
인용
0
참고문헌
초록
Background/Aims: Cytapheresis (CAP) is a novel strategy for ulcerative colitis (UC). However, there is insufficient data on the long-term outcome of UC patients who achieve remission by CAP. This study involved patients with severe UC who refracted to intravenous (iv) corticosteroid. Methods: Forty-seven UC patients who had received CAP therapy for the first time within 1 year after UC diagnosis were followed for 36 months. One of the inclusion criteria was a clinical activity index (CAI) of ≥7 points at the end of a 2-week iv course of corticosteroid therapy. CAP therapy consisted of ten sessions over 10 weeks. Results: CAP induced clinical remission (CAI≤4) in 70.2% patients (33/47). The number of submissions for colectomy was higher for severe UC at entry (CAI≥12, n=25) than for moderately severe UC at entry (7≤CAI ＜12, p=15; p＜0.02). The cumulative rates of avoiding surgery and relapse were 54.5% and 24.2%, respectively, at 36 months in patients who responded to CAP therapy. This was similar to that of iv cyclosporine reported recently. Conclusions: This study suggest that CAP is an effective therapy in patients who are refractory to conventional medications including iv corticosteroid. Increased remission rates should be expected in refractory patients with moderately severe UC.
Abstract
Background/Aims: Cytapheresis (CAP) is a novel strategy for ulcerative colitis (UC). However, there is insufficient data on the long-term outcome of UC patients who achieve remission by CAP. This study involved patients with severe UC who refracted to intravenous (iv) corticosteroid. Methods: Forty-seven UC patients who had received CAP therapy for the first time within 1 year after UC diagnosis were followed for 36 months. One of the inclusion criteria was a clinical activity index (CAI) of ≥7 points at the end of a 2-week iv course of corticosteroid therapy. CAP therapy consisted of ten sessions over 10 weeks. Results: CAP induced clinical remission (CAI≤4) in 70.2% patients (33/47). The number of submissions for colectomy was higher for severe UC at entry (CAI≥12, n=25) than for moderately severe UC at entry (7≤CAI ＜12, p=15; p＜0.02). The cumulative rates of avoiding surgery and relapse were 54.5% and 24.2%, respectively, at 36 months in patients who responded to CAP therapy. This was similar to that of iv cyclosporine reported recently. Conclusions: This study suggest that CAP is an effective therapy in patients who are refractory to conventional medications including iv corticosteroid. Increased remission rates should be expected in refractory patients with moderately severe UC.
참고문헌 (37)
- Allison MC, "Inflammatory bowel disease", pp.9~95 (1998), Mosby
- Truelove SC, "Further experience in the treatment of severe attacks of ulcerative colitis", Lancet, 2, pp.1086~1088 (1978)
- Lichtiger S, "Cyclosporine in severe ulcerative colitis refractory to steroid therapy", N Engl J Med, 330, pp.1841~1845 (1994)
- Serkova NJ, "Biochemical mechanisms of cyclosporine neurotoxicity", Mol Interv, 4, pp.97~107 (2004)
- Present DH, "How to do without steroids in inflammatory bowel disease", Inflamm Bowel Dis, 6, pp.48~57 (2000)
- Sawada K, "Leukocytapheresis therapy, performed with leukocyte removal filter, for inflammatory bowel disease", J Gastroenterol, 30, pp.322~329 (1995)
- Sawada K, "Multicenter randomized controlled trial for the treatment of ulcerative colitis with a Leukocytapheresis column", Curr Pharm Des, 9, pp.307~321 (2003)
- Shimoyama T, "Safety and efficacy of granulocytes and monocyte adsorption apheresis in patients with active ulcerative colitis: a multicenter study", J Clin Apher, 16, pp.1~9 (2001)
- Kanai T, "The logics of leukocytapheresis as a natural biological therapy for inflammatory bowel disease", Expert Opin Biol Ther, 6, pp.453~466 (2006)
- Hanai H, "Positions of selective leukocytapheresis in the medical therapy of ulcerative colitis", World J Gastroenterol, 12, pp.7568~7577 (2006)
- Saniabadi AR, "Adacolumn, an adsorptive carrier based granulocyte and monocyte apheresis device for the treatment of inflammatory and refractory diseases associated with leukocytes", Ther Apher Dial, 7, pp.48~59 (2003)
- Saniabadi AR, "Therapeutic leukocytapheresis for inflammatory bowel disease", Transfus Apher Sci, 37, pp.191~200 (2007)
- Matts SG, "The value of rectal biopsy in the diagnosis of ulcerative colitis", Q J Med, 30, pp.393~407 (1961)
- Jarnerot G, "Intensive intravenous treatment of ulcerative colitis", Gastroenterology, 89, pp.1005~1013 (1985)
- Truelove SC, "Intensive intravenous regimen for severe attacks of ulcerative colitis", Lancet, 1, pp.1067~1070 (1974)
- Sawada K, "Leukocytapheresis in ulcerative colitis: results of a multicenter double-blind treatment", Am J Gastroenterol, 100, pp.1362~1369 (2005)
- Campbell S, "Ciclosporin use in acute ulcerative colitis: a long-term experience", Eur J Gastroenterol Hepatol, 17, pp.79~84 (2005)
- Cohen RD, "Intravenous cyclosporin in ulcerative colitis: a five-year experience", Am J Gastroenterol, 94, pp.1587~1592 (1999)
- D’Haens G, "Intravenous cyclosporine for severe attacks of ulcerative colitis", Gastroenterology, 120, pp.1323~1329 (2001)
- Rayner CK, "Long-term results of low-dose intravenous ciclosporin for acute severe ulcerative colitis", Aliment Pharmacol Ther, 18, pp.303~308 (2003)
- Van Assche G, "Randomized, double-blind comparison of 4 mg", kg versus 2 mg, Gastroenterology, pp.2003, 125[DOI]
- Domènech E, "Azathioprine without oral cyclosporine in the long-term maintenance of remission induced by intravenous cyclosporine in severe, steroid-refractory ulcerative colitis", Aliment Pharmacol Ther, 16, pp.2061~2065 (2002)
- Tanaka T, "In patients with ulcerative colitis, adsorptive depletion of granulocytes and monocytes impacts mucosal level of neutrophils and clinically is most effective in steroid naïve patients", Dig Liver Dis, 40, pp.731~736 (2008)
- Tibble JA, "Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease", Gastroenterology, 119, pp.15~22 (2000)
- Hanai H, "Leukocyte adsorptive apheresis for the treatment of active ulcerative colitis: a prospective, uncontrolled, pilot study", Clin Gastroenterol Hepatol, 1, pp.28~35 (2003)
- McCarthy DA, "Peripheral blood neutrophils in inflammatory bowel disease: morphological evidence of in vivo activation in active disease", Clin Exp Immunol, 86, pp.489~493 (1991)
- Rugtveit J, "Increased macrophage subset in inflammatory bowel disease: apparent recruitment from peripheral blood monocytes", Gut, 35, pp.669~674 (1994)
- Meuret G, "Macrophage turnover in Crohn's disease and ulcerative colitis", Gastroenterology, 74, pp.501~503 (1978)
- Brannigan AE, "Neutrophil apoptosis is delayed in patients with inflammatory bowel disease", Shock, 13, pp.361~366 (2000)
- Cassatella MA, "The production of cytokines by polymorphonuclear neutrophils", Immunol Today, 16, pp.21~26 (1995)
- Nikolaus S, "Increased secretion of pro-inflammatory cytokines by circulating polymorphonuclear neutrophils and regulation by interleukin-10 during intestinal inflammation", Gut, 42, pp.470~476 (1998)
- Mahida YR, "The key role of macrophages in the immunopathogenesis of inflammatory bowel disease", Inflamm Bowel Dis, 6, pp.21~33 (2000)
- Hanauer SB, "Inflammatory bowel disease: epidemiology, pathogenesis, and therapeutic opportunities", Inflamm Bowel Dis, 12(1), pp.S3~9 (2006)
- Actis GC, "Colectomy rate in steroid-refractory colitis initially responsive to cyclosporin: a long-term retrospective cohort study", BMC Gastroenterol, 7, pp.13~ (2007)
- Cohen RD, "Treating ulcerative colitis without medications--“look mom, no drugs!”", Gastroenterology, 128, pp.235~236 (2005)
- Sands BE, "A randomized, double-blind, sham-controlled study of granulocyte", monocyte apheresis for active ulcerative colitis, 2008, pp.135, 400~409
- Hanai H, "Leucocytapheresis for inflammatory bowel disease in the era of biologic therapy", Eur J Gastroenterol Hepatol, 20, pp.596~600 (2008)